Lincoln Pharma files patent for 'Nam Safe'

Ahmedabad-based Lincoln Pharmaceuticals has filed a patent for its new product 'Nam Safe'. The new product is a combination of the pain killer nimesulide with methionine.

The company plans to invest over Rs 5 crore in its research and development in next one year for new formulations.

"Nam Safe is introduced for first time in the world and we are confident to get the patent soon. Our research and development (R&D) team have been working for the product for the past two years. The company is constantly giving more thrust on R&D in formulation with good numbers of scientists are constantly working on various formulations. We will first launch the product in India and then in other markets." Mahendra G Patel, managing director, Lincoln Pharma told Business Standard.

The company targets a turnover of over Rs 50 crore by the end of the current financial year. With the launch of new formulation, the company aims a growth of over 15 per cent in its turn over.

The company has two different manufacturing facilities for betalactum and non-betalactgurm production. The company's Khatraj plant produces only non betalactum products of tablets, capsules, liquid and drypowder, injectables and syrups.